With these premises, we decided to address the influence of ABCB1 and hOCT1 polymorphisms on the response rate and toxicity of first-line nilotinib in the context of a multicenter “real-life” series of 78 CML cases. This evidence concerns the gene SLC22A1 and chronic myelogenous leukemia, BCR-ABL1 positive.